MX374771B - Formulación parenteral de esmolol. - Google Patents

Formulación parenteral de esmolol.

Info

Publication number
MX374771B
MX374771B MX2014013556A MX2014013556A MX374771B MX 374771 B MX374771 B MX 374771B MX 2014013556 A MX2014013556 A MX 2014013556A MX 2014013556 A MX2014013556 A MX 2014013556A MX 374771 B MX374771 B MX 374771B
Authority
MX
Mexico
Prior art keywords
esmolol hydrochloride
solution
parenteral formulation
ready
pure
Prior art date
Application number
MX2014013556A
Other languages
English (en)
Spanish (es)
Other versions
MX2014013556A (es
Inventor
Rudolf Widmann
Original Assignee
Aop Orphan Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48407551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX374771(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aop Orphan Pharmaceuticals Ag filed Critical Aop Orphan Pharmaceuticals Ag
Publication of MX2014013556A publication Critical patent/MX2014013556A/es
Publication of MX374771B publication Critical patent/MX374771B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2014013556A 2012-05-10 2013-05-08 Formulación parenteral de esmolol. MX374771B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12167443 2012-05-10
PCT/EP2013/059594 WO2013167657A1 (en) 2012-05-10 2013-05-08 Parenteral esmolol formulation

Publications (2)

Publication Number Publication Date
MX2014013556A MX2014013556A (es) 2015-01-16
MX374771B true MX374771B (es) 2025-03-06

Family

ID=48407551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013556A MX374771B (es) 2012-05-10 2013-05-08 Formulación parenteral de esmolol.

Country Status (27)

Country Link
US (3) US20150087704A1 (enExample)
EP (1) EP2846776B1 (enExample)
JP (1) JP6220383B2 (enExample)
CN (1) CN104379134A (enExample)
AU (1) AU2013258031B2 (enExample)
BR (1) BR112014027870B1 (enExample)
CA (1) CA2872953C (enExample)
CL (1) CL2014003028A1 (enExample)
DK (1) DK2846776T3 (enExample)
EA (1) EA032344B1 (enExample)
ES (1) ES2794093T3 (enExample)
HR (1) HRP20200897T1 (enExample)
HU (1) HUE049314T2 (enExample)
IL (1) IL235497A0 (enExample)
LT (1) LT2846776T (enExample)
MA (1) MA37500B1 (enExample)
MX (1) MX374771B (enExample)
MY (1) MY173900A (enExample)
NZ (1) NZ701429A (enExample)
PH (1) PH12014502494B1 (enExample)
PL (1) PL2846776T3 (enExample)
PT (1) PT2846776T (enExample)
SI (1) SI2846776T1 (enExample)
TN (1) TN2014000464A1 (enExample)
UA (1) UA115333C2 (enExample)
WO (1) WO2013167657A1 (enExample)
ZA (1) ZA201408149B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019122157A1 (en) * 2017-12-21 2019-06-27 Ipsol Ag A lyophilisate comprising esmolol and adenosine for use in cardioplegia
CN111848420A (zh) * 2020-07-22 2020-10-30 杭州煌森生物科技有限公司 一种盐酸艾司洛尔的新晶型及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI277414B (en) 2001-01-12 2007-04-01 Baxter Int Esmolol formulation
US6310094B1 (en) * 2001-01-12 2001-10-30 Baxter International Inc. Ready-to-use esmolol solution
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2007026771A1 (ja) * 2005-08-31 2007-03-08 Ono Pharmaceutical Co., Ltd. 点滴用注射剤
US20080293814A1 (en) 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
NZ586200A (en) 2007-12-21 2012-06-29 Aop Orphan Pharmaceuticals Ag Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists
CN102106846A (zh) * 2009-12-23 2011-06-29 南京海辰药业有限公司 左旋盐酸艾司洛尔药物组合物及其制备方法

Also Published As

Publication number Publication date
MX2014013556A (es) 2015-01-16
IL235497A0 (en) 2014-12-31
PT2846776T (pt) 2020-05-28
DK2846776T3 (da) 2020-06-15
NZ701429A (en) 2016-04-29
AU2013258031A1 (en) 2014-11-20
MA37500A1 (fr) 2016-03-31
US20150087704A1 (en) 2015-03-26
CA2872953C (en) 2020-04-07
PH12014502494A1 (en) 2015-01-12
BR112014027870A8 (pt) 2023-01-17
MA37500B1 (fr) 2016-12-30
EP2846776B1 (en) 2020-04-15
MY173900A (en) 2020-02-26
US11963940B2 (en) 2024-04-23
CA2872953A1 (en) 2013-11-14
EA201491841A1 (ru) 2015-02-27
HRP20200897T1 (hr) 2020-11-27
US20220249424A1 (en) 2022-08-11
EP2846776A1 (en) 2015-03-18
PH12014502494B1 (en) 2019-11-13
BR112014027870A2 (pt) 2017-06-27
ZA201408149B (en) 2016-08-31
JP2015520142A (ja) 2015-07-16
PL2846776T3 (pl) 2020-09-21
CL2014003028A1 (es) 2015-06-19
UA115333C2 (uk) 2017-10-25
BR112014027870B1 (pt) 2023-04-25
EA032344B1 (ru) 2019-05-31
AU2013258031B2 (en) 2017-08-03
TN2014000464A1 (en) 2016-03-30
SI2846776T1 (sl) 2020-08-31
LT2846776T (lt) 2020-06-25
JP6220383B2 (ja) 2017-10-25
WO2013167657A1 (en) 2013-11-14
CN104379134A (zh) 2015-02-25
US20170326095A1 (en) 2017-11-16
HUE049314T2 (hu) 2020-09-28
HK1204265A1 (en) 2015-11-13
ES2794093T3 (es) 2020-11-17

Similar Documents

Publication Publication Date Title
MX389346B (es) Formulaciones de anticuerpos monoclonales de alta concentración.
HRP20200072T1 (hr) Načini doziranja za spojeve klase ehinokandina
EA201492021A1 (ru) Антительный состав
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
PH12015501931A1 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
EA201592040A1 (ru) Иммуногенная композиция для применения в терапии
MX348418B (es) Composicion ocular que contiene bromfenaco con biodisponibilidad incrementada.
EA201691055A1 (ru) Препараты и способы лечения gd2-положительного рака
PH12014502494B1 (en) Parenteral esmolol formulation
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
EA201500128A1 (ru) Педиатрические жидкие композиции для перорального введения, содержащие непадутант
JO3689B1 (ar) صيغ من الباراسيتامول قابلة للحقن
UA69674U (ru) Способ лечения больных на эритематозно-бульозной рожей
RU2013142835A (ru) Способ лечения ишемического инсульта
TH155633A (th) สูตรผสมแบบฉีดของเอสโมลอล
RU2012110137A (ru) Способ лечения инсулинорезистентности
UA79052U (ru) Способ иммунокоррекции при обострениях хронического бронхита у больных с инсулинорезистентностью
UA69682U (ru) Способ профилактики обострений вирусного гепатита А у взрослых больных
GR1008260B (el) Ενδοφλεβιο σκευασμα λινεζολιδης και μεθοδος για την παρασκευη αυτου
UA69975U (ru) Способ коррекции показателей клеточного звена иммунитета у больных неалкогольным стеатогепатитом
UA69978U (ru) Способ лечения больных первичной рожей
UA64881U (ru) Способ лечения печеночной недостаточности пострадавших с травмой печени
UA69690U (ru) Способ лечения больных с синдромом повышенной утомляемости на фоне хронической тонзиллярной инфекции
UA89638U (ru) Способ лечения больных пожилого возраста с синдромом сосудистых умеренных когнитивных нарушений
AR085988A1 (es) Tratamientos de la infeccion del virus de la hepatitis c

Legal Events

Date Code Title Description
FG Grant or registration